London, UK (PRWEB) March 26, 2015
In the key developed markets, the hypertension market value reached USD 40 billion as of 2013 and is set to decrease through 2020 at a negative CAGR (0.9%) to USD 37.6 billion by 2020; the growth is expected up to 2017 at a 2.6% CAGR and a decline thereafter. The initial growth is expected to be owing to the surging penetration of fixed-dose combination drugs like Azor, Amturnide, Exforge Tribenzor, Edarbyclor, Tekturna HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), a hike in the prevalence population to 190 million at a 0.6% CAGR, and two novel anticipated launches in the pipeline (a combination of Azilsartan and Amlodipine, and Valsartan + AHU377). However, the market’s growth is forecast to slow down starting from 2017 on account of the expiry of the exclusivity of top drug products before and over the forecasted period (Cozaar in 2010; Avapro, Diovan and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna HCT and Tekturna in 2018), low diagnosis rates and a higher degree of generic penetration.
New research report “Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries” elaborated by GBI Research is now available at MarketPublishers.com.
Title: Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries
Published: June, 2014
Price: US$ 4,995.00
The report provides an all-round examination of the hypertension therapeutics marketplace across the 8 major geographies such as the USA, the 5 leading countries of Europe (the UK, Germany, France, Italy and Spain), Canada and Japan. The research publication provides accurate market size estimates for 2013, alongside detailed market forecasts through to end-2020. It also offers a discussion of the epidemiology of the disorder, treatment algorithms, treatment use patterns, an in-depth analysis of the global pipeline in hypertension in tandem with a review of failure rates in clinical studies. An exhaustive assessment of major co-development and licensing deals is included. The study examines the major drivers and restraints of the sector’s growth, casts light on the competitive scenario and also presents the outline the future prospects for the world hypertension therapeutics market.
Reasons to Buy:
- Align one’s product line to the markets with good growth potential.
- Devise market entry and expansion strategies by finding out what regions and therapeutic areas are poised for robust growth in the years to come.
- Devise a more efficient custom country strategy through a profound understanding of major drivers and hindrances in the market for hypertension therapeutics.
- Develop and undertake major strategic initiatives by identifying key focus areas and examining the dominant companies.
- Accelerate one’s market position and make it stronger by finding the right companies for M&As and strategic partnerships.
More new market research reports by the publisher can be found at https://marketpub lishers.com/members/gbiresearch/info.html [GBI Research page __title__ ].